Monitoring cancer in the genes

Israel’s NovellusDx monitors the effect of cancer therapies on a patient’s genetic mutations.  NovellusDx reports to the oncologist on the contribution of the driver mutations to the activation of the signaling pathways.  NovellusDx has just received $2.5 million funds from the VC Orbimed.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *